The impact of pharmacist‐led interventions on blood pressure control among patients with chronic kidney disease: A randomized controlled trial

Introduction Only about 50% of patients with high blood pressure (BP) and chronic kidney disease (CKD) comorbidity have their BP controlled. Objectives The objectives of the study were to determine whether pharmacist‐led interventions reduce mean BP and improve BP control in hypertensive patients wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAACP : Journal of the American College of Clinical Pharmacy 2022-10, Vol.5 (10), p.1062-1074
Hauptverfasser: Okoro, Roland Nnaemeka, Umate, Ibrahim, Ohieku, John David, Yakubu, Sani Ibn, Adibe, Maxwell Ogochukwu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Only about 50% of patients with high blood pressure (BP) and chronic kidney disease (CKD) comorbidity have their BP controlled. Objectives The objectives of the study were to determine whether pharmacist‐led interventions reduce mean BP and improve BP control in hypertensive patients with CKD compared with usual care. Methods This 12‐month prospective, double‐blind, randomized, controlled trial was conducted at two major hospitals in Nigeria. Seventy‐four participants were randomized to the usual care arm serving as the control and 73 participants were randomized to the intervention arm. The intervention arm received home BP monitors, and pharmacological and nonpharmacological (education and training on self‐management of CKD and hypertension, and text messages) interventions. Results Baseline characteristics were similar between the intervention (n = 73) and usual care (n = 74) participants. However, significantly more females were in the intervention arm compared with the usual care arm (71.2% vs 52.7%; P = .021). Compared with the usual care arm, systolic BP (SBP) significantly decreased by 7.12 mmHg from baseline (P = .020) in the intervention arm. Higher proportions of patients gained BP control from baseline to 6 months (27.4% vs 13.5%, P = .095), and from baseline to 12 months (20.5% vs 8.1%, P = .096) in the intervention arm than the usual care. There were no statistical differences, but clinical differences were observed. Conclusion This trial demonstrates that including a clinical pharmacist in a team care setting can improve BP reduction and control in patients with CKD and hypertension. Trial registration ClinicalTrials.gov NCT05254392.
ISSN:2574-9870
2574-9870
DOI:10.1002/jac5.1677